Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 684

1.

Promoters influence the kinetics of transgene expression following adenovector gene delivery.

Chen P, Tian J, Kovesdi I, Bruder JT.

J Gene Med. 2008 Feb;10(2):123-31.

PMID:
18064718
[PubMed - indexed for MEDLINE]
2.

Repeated administration of adenovector in the eye results in efficient gene delivery.

Hamilton MM, Brough DE, McVey D, Bruder JT, King CR, Wei LL.

Invest Ophthalmol Vis Sci. 2006 Jan;47(1):299-305.

PMID:
16384977
[PubMed - indexed for MEDLINE]
Free Article
3.

Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.

Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA, Wadsworth SC, Smith AE, Gregory RJ.

J Virol. 1997 Mar;71(3):2408-16.

PMID:
9032378
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.

Yew NS, Marshall J, Przybylska M, Wysokenski DM, Ziegler RJ, Rafter PW, Li C, Armentano D, Cheng SH.

Hum Gene Ther. 1999 Jul 20;10(11):1833-43.

PMID:
10446923
[PubMed - indexed for MEDLINE]
5.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

PMID:
12627218
[PubMed - indexed for MEDLINE]
Free Article
6.

Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.

Brough DE, Hsu C, Kulesa VA, Lee GM, Cantolupo LJ, Lizonova A, Kovesdi I.

J Virol. 1997 Dec;71(12):9206-13.

PMID:
9371579
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter.

Gill DR, Smyth SE, Goddard CA, Pringle IA, Higgins CF, Colledge WH, Hyde SC.

Gene Ther. 2001 Oct;8(20):1539-46.

PMID:
11704814
[PubMed - indexed for MEDLINE]
Free Article
8.

High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter.

Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH.

Mol Ther. 2001 Jul;4(1):75-82. Erratum in: Mol Ther 2001 Sep;4(3):280.

PMID:
11472109
[PubMed - indexed for MEDLINE]
Free Article
9.

Pharmacogenetic heterogeneity of transgene expression in muscle and tumours.

Lefesvre P, Attema J, van Bekkum D.

BMC Pharmacol. 2003 Aug 28;3:11. Epub 2003 Aug 28.

PMID:
12943556
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Adenovector-mediated hair cell regeneration is affected by promoter type.

Praetorius M, Hsu C, Baker K, Brough DE, Plinkert P, Staecker H.

Acta Otolaryngol. 2010 Feb;130(2):215-22. doi: 10.3109/00016480903019251.

PMID:
20095092
[PubMed - indexed for MEDLINE]
11.

Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery.

Wolff LJ, Wolff JA, SebestyƩn MG.

Hum Gene Ther. 2009 Apr;20(4):374-88. doi: 10.1089/hum.2008.088.

PMID:
19199823
[PubMed - indexed for MEDLINE]
12.

Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice.

Bouchard S, MacKenzie TC, Radu AP, Hayashi S, Peranteau WH, Chirmule N, Flake AW.

J Gene Med. 2003 Nov;5(11):941-50.

PMID:
14601131
[PubMed - indexed for MEDLINE]
13.

Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1alpha promoter and a human chromatin insulator.

Mori-Uchino M, Takeuchi T, Murakami I, Yano T, Yasugi T, Taketani Y, Nakagawa K, Kanda T.

J Gene Med. 2009 Jul;11(7):598-604. doi: 10.1002/jgm.1337.

PMID:
19399759
[PubMed - indexed for MEDLINE]
14.

Evaluation of promoter strength in mouse and rat primary hepatocytes using adenovirus vectors.

Arita E, Kondoh M, Isoda K, Nishimori H, Yoshida T, Mizuguchi H, Yagi K.

Eur J Pharm Biopharm. 2008 Sep;70(1):1-6. doi: 10.1016/j.ejpb.2008.03.013. Epub 2008 Mar 29.

PMID:
18468873
[PubMed - indexed for MEDLINE]
15.

Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.

Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, Comin-Anduix B, Prins RM, Faure-Kumar E, Rozengurt N, Cui Y, Kasahara N, Stripecke R.

Mol Ther. 2007 Jul;15(7):1390-9. Epub 2007 May 1.

PMID:
17505480
[PubMed - indexed for MEDLINE]
16.

Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector.

Lena AM, Giannetti P, Sporeno E, Ciliberto G, Savino R.

J Gene Med. 2005 Aug;7(8):1086-96.

PMID:
15772935
[PubMed - indexed for MEDLINE]
17.

Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors.

Song W, Kong HL, Traktman P, Crystal RG.

Hum Gene Ther. 1997 Jul 1;8(10):1207-17.

PMID:
9215738
[PubMed - indexed for MEDLINE]
18.
19.

Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.

Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW.

Blood. 2001 Mar 1;97(5):1258-65.

PMID:
11222368
[PubMed - indexed for MEDLINE]
Free Article
20.

Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.

Cao B, Bruder J, Kovesdi I, Huard J.

Gene Ther. 2004 Sep;11(17):1321-30.

PMID:
15175641
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk